{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-024218","form_type":"8-K","ticker":"CYCN","cik":"0001755237","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.396502+00:00","generated_at":"2026-06-15T02:40:09.011405+00:00","sec_items":["1.01","2.02","7.01","3.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cyclerion sells zagociguat & CY3018 for $8M cash + 10% equity; CEO to lead NewCo","bullets":["Receives $8M cash at closing and 10% equity in NewCo with anti-dilution protection through $100M post-money.","NewCo investors (Invus, Venrock, J Wood Capital, Sanofi Ventures) commit $81M to develop zagociguat and CY3018.","CEO Peter Hecht will transition to NewCo as CEO; Errol De Souza elected Chair of Cyclerion Board.","Signing triggers $5M equity investment by Hecht at $0.434/share; proceeds plus $8M expected to fund operations for 12+ mos.","Q1 2023 cash $7.2M (down from $13.4M year-end 2022); company to seek later-stage CNS assets under new leadership."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-024218","json":"https://secwatch.observer/filing/0001140361-23-024218.json","markdown":"https://secwatch.observer/filing/0001140361-23-024218.md","text":"https://secwatch.observer/filing/0001140361-23-024218.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1755237/000114036123024218/0001140361-23-024218-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1755237/000114036123024218/brhc20052804_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:40:09.011405+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"010ff35c7731e04ac7e16282679ce4913c01d084","claim":"Cyclerion Therapeutics, Inc. reported financial results for first quarter 2023.","evidence_excerpt":"Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates and first quarter 2023 financial results.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1755237/000114036123024218/0001140361-23-024218-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}